a. To determine: Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene. Introduction: Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Question

Want to see the full answer?

Answer 1

Question

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

Answer number seven do what it says.

Which of the following is the process that is "capable of destroying all forms of microbial life"? Question 37 options: Surgical scrub Sterilization Chemical removal Mechanical removal

After you feel comfortable with your counting method and identifying cells in the various stages of mitosis, use the four images below of whitefish blastula to count the cells in each stage until you reach 100 total cells, recording your data below in Data Table 1. (You may not need to use all four images. Stop counting when you reach 100 total cells.) After totaling the cells in each stage, calculate the percent of cells in each stage. (Divide total of stage by overall total of 100 and then multiply by 100 to obtain percentage.) Data Table 1Stage Totals PercentInterphase Mitosis: Prophase Metaphase Anaphase Telophase Cytokinesis Totals 100 100% To find the length of time whitefish blastula cells spend in each stage, multiply the percent (recorded as a decimal, in other words take the percent number and divide by 100) by 24 hours. (Example: If percent is 20%, then Time in Hours = .2 * 24 = 4.8) Record your data in Data…

Answer 2

Question

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 3

Question

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 4

Question

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 5

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Answer 6

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Answer 7

Chapter 19, Problem 23P

Summary Introduction

a.

To determine:

Whether the gene that codes for EGFR is a tumor-suppressor gene or a proto-oncogene.

Introduction:

Tumor-Suppressor genes are normal genes that are responsible for inhibiting cell proliferation. A proto-oncogene is a normal gene that has the potential to convert in an oncogene due to any mutation.

Answer 8

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Answer 9

Summary Introduction

b.

To determine:

Whether a patient with a GBM expressing EGFRvIII should be treated with a higher or lower dose of X-rays than with patients having GBMs with normal EGFR proteins.

Introduction:

It is given that the cells that express EGFRvIII are difficult to induce to undergo programmed cell death. There are other methods used to kill the cells containing this mutant protein like radiology, chemotherapy, and so on.

Answer 10

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Answer 11

Summary Introduction

c.

To determine:

The method by which the mutant EGFR protein might be responsible for causing cancer.

Introduction:

It is given that EGFR is a transmembrane protein. The N-terminal of this protein has an extracellular part that binds epidermal growth factor and the C-terminal kinase part that is normally activated when EGF binds to EGFR.

Answer 12

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Answer 13

Summary Introduction

d.

To determine:

Whether the drug blocking the kinase activity of EGFR would be a potential treatment for GBMs expressing EGFRvIII or it would make the tumors grow faster.

Introduction:

It is given that Iressa^TM is a drug that blocks the kinase activity of EGFR. The kinase is an enzyme that phosphorylates other proteins.

Answer 14

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Answer 15

Summary Introduction

e.

To determine:

Whether patients with high amounts of ERCC1 mRNAs should be treated with higher or lower doses of cisplatin than patients with normal amounts of ERCC1 mRNAs.

Introduction:

It is given that cisplatin is a platinum compound that is associated with DNA damage and causes cell death. The ERCC1 gene codes for a DNA repair protein.

Answer 16

Expert Solution & Answer

Answer 17

Expert Solution & Answer

Answer 18

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 19

Ch. 19 - For each of the terms in the left column, choose...Ch. 19 - Characterize the differences between tumor cells...Ch. 19 - Prob. 3P Ch. 19 - Prob. 4P Ch. 19 - A carcinogenic compound is placed on the skin of...Ch. 19 - Prob. 6P Ch. 19 - Prob. 7P Ch. 19 - Molecules outside and inside the cell regulate the...Ch. 19 - Put the following steps in the correct ordered...Ch. 19 - a. Would you expect a cell to continue or to stop...

Solution Summary: The author explains that Glioblastoma multiforme (GBM) is the most common and invasive form of brain cancer in humans.

Videos

Want to see the full answer?

Chapter 19 Solutions